Literature DB >> 2354095

Hepatic and extrahepatic disposition of propofol in patients undergoing coronary bypass surgery.

H Lange1, H Stephan, H Rieke, M Kellermann, H Sonntag, J Bircher.   

Abstract

In order to clarify the relative contribution of the liver to the short term disposition of propofol, hepatic blood flow was measured during induction of anaesthesia with an i.v. bolus dose of propofol 2 mg kg-1. Total clearance of the drug was 2390 (SD 340) ml min-1, hepatic extraction 82% and hepatic clearance 1060 (260) ml min-1. During the 60-min period of observation, hepatic extraction of propofol increased from 79% to 92%. It is concluded that, within 1 h, only 44% of the administered dose is removed by the liver. Consequently, drug accumulation may occur with repeated dosing or infusion of propofol. The increase in extraction results presumably from slow release of propofol from the soy-bean emulsion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354095     DOI: 10.1093/bja/64.5.563

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  13 in total

1.  Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain.

Authors:  Haruhiko Hiraoka; Koujirou Yamamoto; Soutarou Miyoshi; Toshihiro Morita; Katsunori Nakamura; Yuuji Kadoi; Fumio Kunimoto; Ryuya Horiuchi
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

2.  Involvement of human liver cytochrome P4502B6 in the metabolism of propofol.

Authors:  Y Oda; N Hamaoka; T Hiroi; S Imaoka; I Hase; K Tanaka; Y Funae; T Ishizaki; A Asada
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 3.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 4.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 5.  Propofol. An update of its use in anaesthesia and conscious sedation.

Authors:  H M Bryson; B R Fulton; D Faulds
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

6.  [Accuracy of target-controlled infusion (TCI) with 2 different propofol formulations].

Authors:  H Ihmsen; C Jeleazcov; J Schüttler; H Schwilden; F Bremer
Journal:  Anaesthesist       Date:  2004-10       Impact factor: 1.041

Review 7.  Anaesthesia for coronary artery surgery--a plea for a goal-directed approach.

Authors:  R I Hall
Journal:  Can J Anaesth       Date:  1993-12       Impact factor: 5.063

Review 8.  Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation.

Authors:  B Fulton; E M Sorkin
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

9.  In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat.

Authors:  A A Raoof; P F Augustijns; R K Verbeeck
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

10.  Effect of enteral versus parenteral feeding on hepatic blood flow and steady state propofol pharmacokinetics in ICU patients.

Authors:  N Van Brandt; P Hantson; Y Horsmans; P Mahieu; R K Verbeeck
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.